NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
12/08/2025
Voltar para busca
Dado oficial do USPTO
NOVOCOL PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Snapshot rápido
ST13
US500000088692164Classe
5, 10, 35, 40, 42, 45
Pedido
88692164
Registro
7697673
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
89
Atualização mais recente
12/08/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 35, 40, 42, 45
Data de depósito
14/11/2019
Data de registro
18/02/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/02/2025
Última transação
12/08/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
2020-00-00
Primeiro uso no comércio
2020-00-00
Código do desenho
3
Tipo de titular
99
Localização do titular
Saint-Maur-des fosses, FR
Examinador
ALLEN, BIANCA
Localização atual
Historical data usage
Descrição da marca
The mark consists of a design element in the top-left corner of overlapping arced lines with the bottom line in red and the top line in blue, with the word "NOVOCOL" in blue lower-case design and underneath to the right the word "PHARMA" in smaller red lower-case design.
Titulares e representantes
Titulares
Septodont Holding
Representantes
Jason J. Mazur ArentFox Schiff LLP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 35Classe 40Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
(Based on 44(e)) Pharmaceutical productsacne medicationallergy medicationantacidsanthelminticsantiarrhythmicsantibiotic creams and ointmentsantibioticsanticoagulantsanticonvulsantsantidepressantsantiemeticsantiflatulantsantihistaminesantihypertensives anti-infectivesanti-inflammatoriesantiparasitesantiviralsburn relief medicationcalcium channel blockerscentral nervous system depressantscentral nervous system stimulantscough treatment medicationdiarrhea medicationfungal medicationsgastro-intestinal pharmaceutical preparationsglaucoma agentshydrocortisonehypnotic agentssedativespain relief medicationtopical and injectable pharmaceutical preparations for dentalendodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparationscorticosteroidshormone replacement therapy preparationsoral contraceptivesthyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infectionsfungal skin infectionsviral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disordersAlzheimer's diseaseParkinson's diseaseHuntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseasesdisorders and infections of the endocrine systemgrowth and thyroid disorders; pharmaceutical preparations for the treatment of diseasesdisorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseasesdisorders and infectionsinfertilitysexually transmitted diseasesincontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseasesurological diseasesinfertilitysexually transmitted diseasesinflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseasesautoimmune diseasesimmunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseasesrespiratory infectionseye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseasesinflammatory bowel diseasesinflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disordersgoutosteoarthritismuscular dystrophyanemia; pharmaceutical preparations for the treatment of metabolic disordersbulimia nervosaanorexiahypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseasesAlzheimer'sHuntington's Diseasecerebral palsy; pharmaceutical preparations for the treatment of neurological disordersbrain injuryspinal cord injuryseizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorderscerebrovascular accident (stroke)Parkinson's diseasemultiple sclerosismyasthenia gravisHuntington's disease; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictionsgambling addictioneating disorders and addictionsnicotine addictionInternet addictiondrug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disordersanxietymood disordersschizophreniacognitive and bipolar disordersepilepsyAlzheimer'scerebral palsyParkinson's diseasemultiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseasesmood disordersanxiety disorderscognitive disordersschizophrenia; pharmaceutical preparations for the treatment of respiratory diseasesdisorders and infections; pharmaceutical preparations for the treatment of skin irritationsbee stingssunburnrashessorescornscallusesacne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous systemcentral nervous system infectionsbrain diseasescentral nervous system movement disordersocular motility disordersspinal cord diseases; pharmaceutical preparations for the treatment of the central nervous systemencephalitisepilepsyAlzheimer'scerebral palsyParkinson's disease; pharmaceutical preparations for the treatment of the diseasesdisorders and infections of the central nervous systembrainmovementocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal systemconnective tissue diseasesbone diseasesspinal diseasesback painfracturessprainscartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseasesherpeshepatitisAcquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatologydermatitisskin pigmentation diseasessexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations for treatment of dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systemsall-purpose disinfectants; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Classe 10
(Based on 44(e)) Drug delivery systemsconsisting of needlessyringesnasal spray bottlesinjection devicesoral and nasal inhalation devicespatch pumpsanesthetic delivery apparatus for medical purposesbut not for use in the fields of diabetes and obesity; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Classe 35
(Based on 44(e)) Business consulting services relating to pharmaceutical manufacturingclinical evaluation and testingregulatory registrationstability studiesmethod developmentformal stabilityregistration batches and commercial production; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Classe 40
(Based on 44(e)) Contract manufacturing of clinical batches of pharmaceuticals; (Based on Use) consulting services relating to pharmaceutical manufacturing and batch biological treatment batches; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Classe 42
(Based on 44(e)) Pharmaceutical drug development servicesthe formulation of new dosage forms and the reformulation of existing drug products; (Based on Use) consulting services relating to clinical testinginspectionresearch of pharmaceuticals; consulting services relating to conducting pharmaceutical stability studies and formal stability studies; consulting services relating to the development of chemical production methods; consulting services relating to registration batch research and commercial pharmaceutical products development; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Classe 45
(Based on 44(e)) Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; (Based on Use) consulting services relating to pharmaceuticals in the field of regulatory complianceregulatory registration; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
89 publicações encontradas
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
23/07/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
14/07/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
21/02/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/02/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
18/02/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
27/01/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/01/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/01/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/01/2025
EX1G
SOU EXTENSION 1 GRANTED
04/01/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/01/2025
IUAF
USE AMENDMENT FILED
16/10/2024
EXT1
SOU EXTENSION 1 FILED
16/10/2024
EISU
TEAS STATEMENT OF USE RECEIVED
16/10/2024
EEXT
SOU TEAS EXTENSION RECEIVED
16/10/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
16/04/2024
CHPB
POST PUBLICATION AMENDMENT - ENTERED
12/03/2024
APET
ASSIGNED TO PETITION STAFF
11/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/03/2024
PUBO
PUBLISHED FOR OPPOSITION
20/02/2024
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
08/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
31/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/01/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
16/01/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/01/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
16/01/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/12/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
21/12/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
02/10/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
02/10/2023
CNSI
SUSPENSION INQUIRY WRITTEN
02/10/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
27/09/2023
DOCK
ASSIGNED TO EXAMINER
18/09/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
02/09/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
08/02/2023
GNSL
LETTER OF SUSPENSION E-MAILED
08/02/2023
CNSL
SUSPENSION LETTER WRITTEN
08/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/02/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/02/2023
ALIE
ASSIGNED TO LIE
08/02/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/02/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
08/08/2022
GNSI
INQUIRY TO SUSPENSION E-MAILED
08/08/2022
CNSI
SUSPENSION INQUIRY WRITTEN
08/08/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
18/07/2022
DOCK
ASSIGNED TO EXAMINER
09/03/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/03/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/03/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/03/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/03/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/01/2022
GNSL
LETTER OF SUSPENSION E-MAILED
10/01/2022
CNSL
SUSPENSION LETTER WRITTEN
10/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/01/2022
ALIE
ASSIGNED TO LIE
03/01/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
28/12/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/07/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/07/2021
CNSI
SUSPENSION INQUIRY WRITTEN
01/07/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
30/12/2020
GNSL
LETTER OF SUSPENSION E-MAILED
30/12/2020
CNSL
SUSPENSION LETTER WRITTEN
30/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/12/2020
ALIE
ASSIGNED TO LIE
28/12/2020
ALIE
ASSIGNED TO LIE
16/12/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
21/09/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
18/09/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
18/09/2020
CNSI
SUSPENSION INQUIRY WRITTEN
18/09/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
18/03/2020
GNSL
LETTER OF SUSPENSION E-MAILED
18/03/2020
CNSL
SUSPENSION LETTER WRITTEN
18/03/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/03/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
20/02/2020
GNRT
NON-FINAL ACTION E-MAILED
20/02/2020
CNRT
NON-FINAL ACTION WRITTEN
20/02/2020
DOCK
ASSIGNED TO EXAMINER
19/02/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
21/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/11/2019
NWAP
NEW APPLICATION ENTERED
18/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NOVOCOL PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.